Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating tabelecleucel, an allogeneic T-cell immunotherapy, for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease EBV PTLD in patients after failure of rituximab or rituximab plus chemotherapy. This phase 3, multicenter, open-label trial focuses on participants who have undergone solid organ transplant or allogeneic hematopoietic cell transplant and whose disease has not responded to prior standard treatments. Participants receive intravenous tabelecleucel in 5-week cycles, with doses given on Days 1, 8, and 15 of each cycle, followed by observation through Day 35. Treatment continues until the participant achieves a maximal response, experiences unacceptable side effects, starts other therapies, or fails the tabelecleucel treatment. The study includes different cohorts based on transplant type and prior therapies, and all participants have confirmed availability of partially HLA-matched tabelecleucel. Throughout the study, participants undergo assessments including PET-CT or MRI scans to evaluate disease status, with additional brain imaging if central nervous system involvement exists. Researchers monitor response rates, duration of response, overall survival, and safety events such as allograft loss or rejection over a follow-up period of up to five years. Participants are observed closely to understand the benefits and risks of tabelecleucel in this condition.